You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / ABIM MOC

Paris Pearls: Targeting Antibody-Drug Conjugates in Solid Tumors

  • Authors: Aditya Bardia, MD, MPH; Marina Garassino, MD; David O’Malley, MD
  • CME / ABIM MOC Released: 9/28/2022
  • Valid for credit through: 9/28/2023
Start Activity

  • Credits Available

    Physicians - maximum of 0.50 AMA PRA Category 1 Credit(s)™

    ABIM Diplomates - maximum of 0.50 ABIM MOC points

    You Are Eligible For

    • Letter of Completion
    • ABIM MOC points

Target Audience and Goal Statement

This activity is intended for oncologists, pathologists, obstetricians/gynecologists, pulmonologists, and other members of the multidisciplinary care team. 

The goal of this activity is for learners to be better able to understand the latest data evaluating ADCs for the treatment of solid tumors and how best to incorporate these data into the clinical management of affected patients.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Recent clinical trial data evaluating ADCs for the management of patients with solid tumors 
  • Have greater competence related to
    • Individualizing care for patients with solid tumors who would be eligible for ADC-directed therapy  
  • Demonstrate greater confidence in their ability to
    • Incorporate recent clinical trial data into the care of patients with solid tumors


Disclosures

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.


Faculty

  • Aditya Bardia, MD, MPH

    Director
    Breast Cancer Research
    Massachusetts General Hospital Cancer Center
    Harvard Medical School
    Boston, Massachusetts

    Disclosures

    Aditya Bardia, MD, MPH, has the following relevant financial relationships:
    Consultant or advisor for: Daiichi Pharma/AstraZeneca; Eli Lilly; Foundation Medicine; Genentech; Immunomedics/Gilead; Merck; Novartis; Pfizer, Inc.; Phillips; Radius Health; Sanofi
    Research funding from: Daiichi Pharma/AstraZeneca; Eli Lilly; Genentech; Immunomedics/Gilead; Merck; Novartis; Pfizer, Inc.; Radius Health; Sanofi

  • Marina Garassino, MD

    Professor of Medicine
    Lung Cancer Program of Chicago
    Department of Hematology/Oncology
    University of Chicago
    Chicago, Illinois

    Disclosures

    Marina Garassino, MD, has the following relevant financial relationships: 
    Consultant or advisor for: AstraZeneca; Blueprint; Boehringer Ingelheim Italia; Bristol Myers Squibb Company; Celgene; Daiichi Sankyo; Ignyta; Incyte; Inivata; Janssen; Medimmune; Merck; Merck Sharp & Dohme, Corp.; Mirati; Novartis; Ose Immuno; Pfizer; Regeneron; Roche; Sanofi; Seattle Genetics; Takeda
    Research funding from: AstraZeneca; Boehringer Ingelheim Italia; Bristol Myers Squibb Company; Celgene; Foundation Medicine; GlaxoSmithKline; Ignyta; Incyte; Lilly; Medimmune; Merck Sharp & Dohme, Corp.; Novartis; Pfizer; Roche; Spectrum; Takeda; Tiziana

  • David O’Malley, MD

    Professor, Department of Obstetrics and Gynecology
    The Ohio State University College of Medicine
    Director, Division of Gynecologic Oncology
    The Ohio State University Comprehensive Cancer Center
    Columbus, Ohio

    Disclosures

    David O’Malley, MD, has the following relevant financial relationships:
    Consultant or advisor for: AbbVie; AdaptImmune; Agenus, Inc.; Arquer Diagnostics; Arcus Biosciences, Inc.; AstraZeneca; Atossa Therapeutics; Boston Biomedical; Cardiff Oncology; Celcuity; Clovis Oncology; Corcept Therapeutics; Duality Bio; Eisai; Elevar; Exelixis; Genentech Inc.; Genelux; GlaxoSmithKline; Hoffmann-La Roche Inc.; ImmunoGen, Inc.; Imvax; InterVenn; INXMED; IOVANCE Biotherapeutics; Janssen; Jazz Pharmaceuticals; Laekna; Leap Therapeutics, Inc.; Luzsana Biotechnology; Merck & Co.; Merck Sharp & Dohme Corp.; Mersana Therapeutics, Inc.; Myriad; Novartis; NovoCure; OncoC4, Inc.; Onconova; Regeneron Pharmaceuticals, Inc.; RepImmune; R Pharm; Roche Diagnostics; Seagen Inc.; Sorrento; Sutro Biopharma; Tarveda Therapeutics; Toray; Trillium; Umoja; Verastem, Inc.; VBL Therapeutics; Vincerx Pharma; Zencor; Zentalis
    Research funding from: Abbvie; Advaxis; Agenus, Inc.; Alkermes; Aravive, Inc.; Arcus Biosciences, Inc.; AstraZeneca; Atossa Therapeutics; BeiGene USA, Inc.; Boston Biomedical; BristolMyersSquibb; Clovis Oncology; Deciphera Pharma; Eisai; EMD Serono, Inc.; Exelixis; Genentech, Inc.; Genmad; GlaxoSmithKline; Hoffman-La Roche Inc.; ImmunoGen, Inc.; Incyte Corporation; IOVANCE Biotherapeutics; Karyopharm; Leap Therapeutics, Inc.; Merck & Co.; Merck Sharp & Dohme Corp.; Mersana Therapeutics, Inc.; Novartis; NovoCure; NGR Oncology; OncoC4, Inc.; OncoQuest Inc.; Pfizer Inc.; Precision Theerapeutics, Inc.; Prelude Therapeutics; Regeneron Pharmaceuticals, Inc.; Rubius Therapeutics; Seagen Inc.; Sutro Biopharma; TESARO; Verastem, Inc.
    Contracted researcher for: Abbvie; Advaxis; Agenus, Inc.; Alkermes; Aravive, Inc.; Arcus Biosciences, Inc.; AstraZeneca; Atossa Therapeutics; BeiGene USA, Inc.; Boston Biomedical; BristolMyersSquibb; Clovis Oncology; Deciphera Pharma; Eisai; EMD Serono, Inc.; Exelixis; Genentech, Inc.; Genmad; GlaxoSmithKline; Hoffman-La Roche Inc.; ImmunoGen, Inc.; Incyte Corporation; IOVANCE Biotherapeutics; Karyopharm; Leap Therapeutics, Inc.; Merck & Co.; Merck Sharp & Dohme Corp.; Mersana Therapeutics, Inc.; Novartis; NovoCure; NGR Oncology; OncoC4, Inc.; OncoQuest Inc.; Pfizer Inc.; Precision Theerapeutics, Inc.; Prelude Therapeutics; Regeneron Pharmaceuticals, Inc.; Rubius Therapeutics; Seagen Inc.; Sutro Biopharma; TESARO; Verastem, Inc.

Editor

  • Stephanie Baumhover, PharmD, BCPS

    Medical Education Director, Medscape, LLC

    Disclosures

    Stephanie Baumhover, PharmD, BCPS, has no relevant financial relationships.

Compliance Reviewer

  • Leigh Schmidt, MSN, RN, CNE, CHCP

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Leigh Schmidt, MSN, RN, CNE, CHCP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.


Accreditation Statements



In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / ABIM MOC

Paris Pearls: Targeting Antibody-Drug Conjugates in Solid Tumors

Authors: Aditya Bardia, MD, MPH; Marina Garassino, MD; David O’Malley, MDFaculty and Disclosures

CME / ABIM MOC Released: 9/28/2022

Valid for credit through: 9/28/2023

processing....

Contents of This CME Activity

All sections of this activity are required for credit.

Targeting Antibody-Drug Conjugates in Breast Cancer

Dr Aditya Bardia discusses the latest data from ESMO 2022 on Antibody-Drug Conjugates in breast cancer.
Aditya Bardia, MD, MPH

Targeting Antibody-Drug Conjugates in Lung Cancer

Hear Dr Marina Garassino review the highlights of Antibody-Drug Conjugates in lung cancer from ESMO 2022.
Marina Garassino, MD

Targeting Antibody-Drug Conjugates in Ovarian Cancer

Dr David O’Malley summarizes the exciting developments using Antibody-Drug Conjugates in ovarian cancer from ESMO 2022.
David O’Malley, MD
 

Learning Feedback Questions

Please answer these questions to complement your learning experience.